The UK and US have forged a landmark trade agreement that will keep no levies on UK medicine products being sold in the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has committed to increase funding on drugs through the National Health Service (NHS). This pledge ensures that duties on these key exports will be held at zero for a timeframe of the next three years.
This development follows earlier statements to hike import taxes on patented drug imports, with potential rates mentioned as high as 100%.
"This arrangement with the UK bolsters the worldwide climate for new treatments and brings long-overdue balance to American-British drug exports," a release declared.
Trade Significance
Drugs constitute one of the Britain's biggest exports to the US, which is by far the largest destination for leading UK drugmakers.
Statistics indicate that in the 12 months leading up to the third quarter, the UK sold pharmaceutical products worth billions to the US. This figure accounted for 17.4% of British export trade in that period.
"This agreement safeguards employment, boosts investment and sets the stage for the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary remarked.
Detailed NHS Changes
The deal involves several specific changes from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to double overall public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Refund Ceiling: The amount manufacturers must pay back to the NHS to prevent overspending will be capped at fifteen percent. Previously, refunds exceeded twenty percent.
Recent Tensions
The pact comes amid a ongoing dispute between the sector and the British authorities over spending levels and approval rates.
This friction were exacerbated by arguments that American customers were paying several times more for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several significant drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar expansions have been announced toward American operations.
A senior figure stated that the NHS had to spend more on medicines, noting that its budget allocation on drugs had decreased as a proportion of its resources over the last ten years.